Uchl5 Ubiquitin C Terminal Hydrolase L5 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Uchl5 Ubiquitin C Terminal Hydrolase L5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Gene Symbol | UCHL5 | [4]
| Full Name | Ubiquitin C-Terminal Hydrolase L5 | [5]
| Chromosomal Location | 1p36.21 | [6]
| NCBI Gene ID | 51377 | [7]
| Ensembl ID | ENSG00000166333 |
| UniProt ID | Q9Y5K5 |
| Associated Diseases | Parkinson's disease, Alzheimer's disease, Cancer |
UCHL5 encodes a ubiquitin C-terminal hydrolase that hydrolyzes ubiquitin monomers and chains. It is part of the ubiquitin-proteasome system (UPS) and plays a role in protein degradation and recycling.
UCHL5 is expressed in most tissues:
In the brain:
The UPS is the primary system for protein degradation in eukaryotic cells:
This page was created as part of the NeuroWiki gene pages project.
Uchl5 Ubiquitin C Terminal Hydrolase L5 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Uchl5 Ubiquitin C Terminal Hydrolase L5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Matsumoto et al. UCHL5 and the ubiquitin-proteasome system (2023). 2023. ↩︎
Kim et al. UCHL5 in Parkinson's disease and alpha-synuclein degradation (2022). 2022. ↩︎
Liu et al. UCHL5 and Alzheimer's disease pathology (2022). 2022. ↩︎
Zhang et al. UCHL5 inhibitors as cancer therapeutics (2021). 2021. ↩︎
Todi et al. Ubiquitin C-terminal hydrolases in neurodegeneration (2021). 2021. ↩︎
Wilkinson et al. Structure and function of UCHL5 (2020). 2020. ↩︎
Baker et al. Deubiquitinating enzymes in protein quality control (2020). 2020. ↩︎